PRNB - Principia Bio accelerates timeline in study of lead drug in pemphigus December, 30 2019 10:24 AM Principia Biopharma Inc. Principia Biopharma (PRNB -3.2%) now expects final data from its Phase 3 clinical trial evaluating lead candidate PRN1008 in pemphigus patients in H2 2021 instead of H1 2022.More news on: Principia Biopharma Inc., Healthcare stocks news, Read more ...